1. Home
  2. CARG vs MLYS Comparison

CARG vs MLYS Comparison

Compare CARG & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CarGurus Inc.

CARG

CarGurus Inc.

HOLD

Current Price

$34.23

Market Cap

2.6B

Sector

Technology

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$28.27

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CARG
MLYS
Founded
2005
2019
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.3B
IPO Year
2017
2023

Fundamental Metrics

Financial Performance
Metric
CARG
MLYS
Price
$34.23
$28.27
Analyst Decision
Buy
Strong Buy
Analyst Count
11
7
Target Price
$38.32
$48.67
AVG Volume (30 Days)
828.3K
797.8K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
675.00
37.43
EPS
0.87
N/A
Revenue
$316,861,000.00
N/A
Revenue This Year
$13.89
N/A
Revenue Next Year
$8.91
N/A
P/E Ratio
$39.80
N/A
Revenue Growth
59.92
N/A
52 Week Low
$26.39
$22.30
52 Week High
$41.22
$47.65

Technical Indicators

Market Signals
Indicator
CARG
MLYS
Relative Strength Index (RSI) 40.49 62.52
Support Level $32.67 $25.42
Resistance Level $36.46 $31.26
Average True Range (ATR) 1.10 1.21
MACD -0.39 0.29
Stochastic Oscillator 8.38 82.25

Price Performance

Historical Comparison
CARG
MLYS

About CARG CarGurus Inc.

CarGurus Inc is a company that acts as an online automotive marketplace connecting buyers and sellers of new and used cars. It provides three types of marketplace Listing products, Restricted Listings, and Enhanced or Featured Listings, through which it offers real-time and historical data analyzing the connections and pricing analysis. The listing platforms offer auto manufacturers and others to buy advertising on the company's site and target consumers based on the make, model, and zip code of the cars. The company operates through two segments, namely U.S. Marketplace and Digital Wholesale. It generates maximum revenue from the U.S. Marketplace segment. Geographically, the company derives its key revenue from the United States and the rest from international markets.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: